Association of tear proteins with Meibomian gland disease and dry eye symptoms

2010 ◽  
Vol 95 (6) ◽  
pp. 848-852 ◽  
Author(s):  
L. Tong ◽  
L. Zhou ◽  
R. W. Beuerman ◽  
S. Z. Zhao ◽  
X. R. Li
2021 ◽  
pp. 22-24
Author(s):  
V. Meenakshi ◽  
Saswathi Bhushan ◽  
T. Jyothirmayi

AIM: To evaluate tear lm status in cases of Parkinson's Disease and compare with a study group METHODS:50 patients of Parkinson's Disease and 50 age-gender matched controls were included in this study. Both groups underwent detailed history regarding dry eye symptoms,tear lm evaluation using slit-lamp bio-microscopy, uorescein staining, tear meniscus height, tear breakup time, Schirmer test, blink rate. Statistical analysis was done with Statistical Package for Social Sciences [SPSS] - Version 22.0 Released 2013 version RESULTS: There was a signicant difference between the various groups in terms of distribution of Meibomian Gland Disease 72.0% of the Case group as compared to 40% of control group had Meibomian Gland Disease,There was a signicant difference between the various groups in terms of distribution of Tear Meniscus Height <0.25Mm , Case group had the larger proportion of Tear Meniscus Height of <0.25Mm .There was a signicant difference between the various groups in terms of distribution of Tear Breakup Time <5 Sec, Schirmer's Test <5Mm in 5Min and Blink Rate <10 .There was no signicant difference between the various groups in terms of distribution of corneal Staining and dry eye symptoms. CONCLUSION: The study concluded that patient of Parkinson's disease had higher dry eye symptoms and Meibomian gland disease Also they have reduced Tear miniscus height,Tear lm break up time,Schirmer test I and Blink rate


2018 ◽  
Vol 41 ◽  
pp. S35-S36
Author(s):  
Carolina Kunnen ◽  
Percy Lazon de la Jara ◽  
Brien Holden ◽  
Eric Papas

2021 ◽  
Vol 8 ◽  
Author(s):  
Kangcheng Liu ◽  
Yau Kei Chan ◽  
Xia Peng ◽  
Ruolan Yuan ◽  
Min Liao ◽  
...  

Purpose: To explore the therapeutic effect of a dietary supplement on dry eye with meibomian gland dysfunction (MGD).Methods: Sixty patients with MGD-related dry eye were included in this prospective and randomized, placebo-controlled study. All the subjects were treated with eye hot compress, artificial tears, and antibiotic ointment. After that, the patients received dietary supplementary or placebo daily for 12 weeks. The dry eye signs, function of MG, and visual quality of the patients were assessed at 4, 8, and 12 weeks after the treatment.Results: Twelve weeks after the treatment, patients who received dietary supplement had a significantly better improvement of dry eye symptoms, in terms of ocular surface diseases index and tear breaking-up time (TBUT), than those who received placebo (P &lt; 0.05). The functions of MG, in terms of meibum quality and MG exclusion and MG obstruction scores, were significantly improved in both dietary supplement and placebo groups (P &lt; 0.05). Patients who received dietary supplement had a significantly better improvement in the MG structure, in terms of acinar diameter and acinar density, than those who received placebo (P &lt; 0.05). The number of inflammatory cells near MG was significantly lower in the dietary supplement group when compared with the placebo group (P &lt; 0.05). The objective visual quality was significantly improved in the dietary supplement group, but not in the placebo group (P &lt; 0.05).Conclusion: The dietary supplement can effectively improve the symptoms and signs of MGD-related dry eye, reduce the inflammatory reaction of MG, restore the gland structure, and indirectly improve the visual quality.


2020 ◽  
Vol 18 (4) ◽  
pp. 604-612 ◽  
Author(s):  
Calesta Hui Yi Teo ◽  
Hon Shing Ong ◽  
Yu-Chi Liu ◽  
Louis Tong

2020 ◽  
Vol 9 (9) ◽  
pp. 2814
Author(s):  
Sachiko Inoue ◽  
Motoko Kawashima ◽  
Reiko Arita ◽  
Ai Kozaki ◽  
Kazuo Tsubota

We prospectively evaluated the relationship between meibomian gland dysfunction (MGD) and Graves’ ophthalmopathy (GO) in 19 patients (38 eyes) with subjective dry eye symptoms, compared to 14 age-matched normal participants (14 eyes). Extraocular muscle and lacrimal gland enlargement were evaluated by magnetic resonance imaging (MRI). Ocular surface examinations included fluorescein staining for keratoconjunctival epithelial damage, tear breakup time (TBUT) evaluation, and Schirmer’s test. Dry eye symptoms were evaluated with the Dry Eye-related Quality-of-Life Score (DEQS) questionnaire. Lid-margin abnormalities, meibum grade, and meiboscores were assessed using meibography. Clinical activity scores and T2 signal intensity ratios were used to define GO activity. All GO patients had obstructive MGD and 79% exhibited levator muscle enlargement. Ocular surface parameters of TBUT (p = 0.000), meibum score (p = 0.000), eyelid vasculitis (p = 0.000), meiboscore of the upper lid (p = 0.002), total meiboscores (p = 0.001), and DEQS (p = 0.000) significantly differed between GO patients and normal subjects. In addition, GO patients had significantly more abnormalities of the central region of the upper eyelid than normal subjects (p = 0.000). Thus, MGD might be related to eye discomfort and deterioration of the ocular surface in GO patients. Inflammation and morphological meibomian gland changes might be characteristic of GO.


2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Yinying Zhao ◽  
Jialu Xie ◽  
Junhua Li ◽  
Yana Fu ◽  
Xiaolei Lin ◽  
...  

Purpose.To investigate the safety and efficacy of monocular treatment for elderly Chinese patients with meibomian gland dysfunction (MGD) with an automated thermodynamic system.Methods.This study was a prospective, examiner-masked, contralateral eye clinical trial. The eye perceived by the patient to be worse (test eye) received a 12-minute LipiFlow treatment, while the other eye served as control. All patients were examined before treatment and one week, one month, and three months after treatment. Clinical parameters included dry eye symptoms, lipid layer thickness (LLT), partial blink (PB) ratio, invasive tear breakup time (ITBUT) and cornea staining, Schirmer I test, meibomian glands yielding liquid secretion (MGYLS), and meibomian gland dropout.Results.A total of 29 patients were examined during the three-month follow-up. At each posttreatment visit, they had a significant reduction in dry eye symptoms accompanied by an increase of ITBUT and MGYLS and a reduction in corneal staining compared with the baseline parameters. There was a significant improvement in MGYLS and ITBUT in the test eye compared with the control eye. Other clinical parameters were not statistically significant.Conclusion.LipiFlow is an effective treatment for patients with MGD. Monocular treatment with LipiFlow may be a cost-effective treatment option to those afflicted with MGD in the developing world.


Sign in / Sign up

Export Citation Format

Share Document